via Tel Aviv University
Novel RNA technology – Boosting personalized cancer care
Researchers from Tel Aviv University proved that a drug delivery system based on lipid nanoparticles can utilize RNA to overcome resistance to both chemotherapy and immunotherapy in cancer treatments. The study opens a new path to a personalized and precisely targeted battle against cancer. The results were published in the scientific journal Advanced Materials.
The study was led by TAU Vice President for R&D Prof. Dan Peer, Head of the Laboratory of Precision Nanomedicine at the Shmunis School of Biomedicine and Cancer Research, Wise Faculty of Life Sciences, and a member of the Roman Abramovich Center for Nanoscience and Nanotechnology, together with post-doctoral researcher Dr. Seok-Beom Yong of South Korea. The study was funded via an ERC grant from the European Union and a research scholarship from the Korean government.
Chemo-immunotherapy, which combines chemotherapy with immunotherapy, is considered the most advanced standard of care for various types of cancer. While chemotherapy destroys cancer cells, immunotherapy encourages the cells of the immune system to identify and attack the remaining cancer cells. However, many patients fail to respond to chemo-immunotherapy, which means that the treatment is not sufficiently targeted. Prof. Peer and his team are the first in the world to prove the feasibility of a drug delivery system based on lipid nanoparticles that release their load only at the specifically targeted cells – cancer cells for chemotherapy and immune cells for immunotherapy.
“In our system a single nanoparticle is capable of operating in two different arenas,” explains Prof. Peer. “It increases the sensitivity of cancer cells resistant to chemotherapy, while also reinvigorating immune cells and increasing their sensitivity to cancer cells. Thus, with one precisely targeted nanoparticle we provide two different treatments, at very different sites. We tested this system in two types of lab models – one for metastasized melanoma, and the other for a local solid tumor. In both populations we observed positive effects of our delivery system.”
The new development by Prof. Peer’s team builds from another recent discovery: an enzyme called HO1 is used by cancer cells for both resisting chemotherapy and concealing themselves from the immune system. Silencing HO1 in the tumor is thus considered an optimal strategy in clinical research, but so far, all attempts to silence the enzyme led to severe side effects.
“Chemo-resistant tumors pose a significant challenge in our endless battle against cancer,” says Prof. Peer. “We aim to silence the enzyme HO1 which enables tumors to develop resistance to chemotherapy, and to conceal themselves from the immune system. But existing methods for silencing HO1 resemble using an F-16 fighter jet to blast a tiny ant. Our new nanodrug knows how to precisely target the cancer cells, silence the enzyme, and expose the tumor to chemotherapy, without causing any damage to surrounding healthy cells. Afterwards, the same nanoparticle goes on to the T-cells of the immune system and reprograms them to identify cancer cells. Active, highly aggressive tumors are able to conceal themselves from the immune system, and we restore the immune cells’ ability to recognize the cancer as a foreign body and attack it.”
“This is the first instance of a single drug based on an RNA-loaded nanoparticle doing two very different, even opposite jobs,” adds Prof. Peer. “This is only an initial study, but it has enormous potential in the ongoing fight against cancer.”
Original Article: The nanodrug that attacks the cancer twice A single nanoparticle does two jobs: enhancing the effectiveness of chemotherapy and reinvigorating the immune system
More from: Tel Aviv University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Personalized cancer care
- OakLeaf Clinics launches oncology services to fill cancer care gap left by Chippewa Valley HSHS closures
Cancer surveillance care is highly personalized and is unique to the type of cancer diagnosis each patient had and the treatment received. Each diagnosis has a National Comprehensive Cancer Network ...
- Celebrating Excellence In Cancer Research, SAASCR Honors Scientists
Their groundbreaking research has transformed our understanding of hematologic malignancies and cancer disparities, driving progress towards personalized therapeutics ... Their dedication to advancing ...
- 5 best care packages for someone going through chemotherapy
A personalized care package can significantly uplift someone’s spirits ... Remember, in the fight against cancer, small acts of kindness can have an immense impact, offering hope and love when they ...
- The New Frontier: How Smartphone Data Can Revolutionize Cancer Care
Patient-generated "passive data," collected from smartphones, offers an alternative – continuous, real-time insights into the health and behavior of those living with ...
- Intermountain McKay-Dee Hospital brings comprehensive cancer care close to home for residents of northern Utah
OGDEN, Utah (ABC4 Utah) – Intermountain McKay-Dee Hospital is bringing cancer care close to home for residents of Northern Utah with a new state-of-the-art, comprehensive, and personalized cancer ...
Go deeper with Google Headlines on:
Personalized cancer care
[google_news title=”” keyword=”personalized cancer care” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
RNA technology
- MIT Technology Review
AlphaFold 3 can predict how DNA, RNA and other molecules interact, further cementing its leading role in drug discovery and research. Who will benefit? When wastewater surveillance turns into a hunt ...
- Google DeepMind’s new AI can model DNA, RNA, and ‘all life’s molecules’
AlphaFold 3 goes beyond that and can model DNA, RNA, and smaller molecules called ligands, expanding the model’s capability for scientific use. DeepMind says the new model shows a 50 percent ...
- DeepMind’s new AlphaFold 3 expands to DNA, RNA modeling
Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing ...
- World-Renowned Scientists Call for RNA Counterpart to Human Genome Project
From bioterrorism to cybersecurity, RNA could help us confront serious threats to the nation. WASHINGTON, DC / ACCESSWIRE / May 8, 2024 / A group of renowned scientists today will be holding a ...
Go deeper with Google Headlines on:
RNA technology
[google_news title=”” keyword=”RNA technology” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]